嵌合式抗原受体T细胞疗法的现状及其耗尽机制

Huiwen Zhang1,2, Juwei Gao1,2, Zipeng Zhang2

  • 1School of Pharmacy, Shandong Second Medical University, Weifang, Shandong, P.R. China.

Immunotherapy
|September 15, 2025
PubMed
概括

化学抗原受体 (CAR) T细胞疗法在瘤学方面表现有前途,但患有T细胞枯竭. 了解和抑制CAR-T细胞功能障碍对于提高抗瘤疗效和持续性至关重要.